Global Bispecific Antibody Is Expected To Surpass US$ 40 Billion By 2029 Says Kuick ResearchDelhi, Nov. 25, 2024 (GLOBE ...

US FDA approves Roche’s companion diagnostic to identify patients with biliary tract cancer eligible for HER2-targeted treatment with Ziihera: Tucson, Arizona Tuesday, November ...

The U.S. Food and Drug Administration approved Jazz Pharmaceuticals' drug, zanidatamab-hrii, for the treatment of a type of ...

Patients in the open-label phase II trial had progressed on at least one gemcitabine-containing regimen and received ...

The US Food and Drug Administration (FDA) has granted accelerated approval to Ziihera (zanidatamab-hrii) for the treatment of adults with previously treated, unresectable or metastatic HER2-positive ...

The U.S. Food and Drug Administration on Tuesday declined full approval for Intercept Pharmaceuticals' liver disease drug, ...

Thanks to the living donor program at Children's Hospital Colorado, a Texas girl found a match for a new liver.

In the United States, Ziihera is indicated for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an ...

Ziihera is the first dual HER2-targeted bispecific antibody approved in the U.S. for HER2-positive biliary tract cancer ...

Learn more about a new treatment for biliary tract cancers with high levels of HER2. The drug zanidatamab has been approved ...

Currently, chemotherapy remains a common treatment for biliary tract cancers, which have a limited survival rate.